CALGB 90601: Follow-Up Form Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer NCT00942331 Source Form: NCI FormBuilder:


Versions (2) ▾
  1. 8/26/12
  2. 1/8/15
Uploaded on:

January 8, 2015

No DOI assigned. To request one please log in.
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Follow-Up Form Bladder Cancer (NCT00942331)

No Instruction available.

  1. StudyEvent: CALGB 90601: Follow-Up Form
    1. No Instruction available.
Are data amended
Vital Status
Patient's Vital Status
Primary Cause of Death
Performance Status
Treatment Status
Treatment Status (Mark one with an X)
Disease Follow-up Status
Has the patient had a documented clinical assessment for this cancer? (since submission of the previous follow-up form)
Measurable Disease Response
Response Status at This Assessment
Sites of Progression
Notice Of New Primary
Has a new primary cancer or MDS been diagnosed that has not been previously reported?
Long-term Toxicity
Has the patient experienced post diagnosis of progression or new primary, any severe (Grade > 3), long-term toxicity that has not been previously reported
Non-protocol Therapy
Has the patient received any non-protocol cancer therapy during this reporting period?
Specify (If yes,)

Similar models